Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study

Eur J Cancer. 2024 Mar:199:113534. doi: 10.1016/j.ejca.2024.113534. Epub 2024 Jan 15.

Abstract

Background: Among patients with renal cell carcinoma (RCC), bone and visceral metastases have a poor prognosis, while endocrine gland metastases have a more favorable prognosis. Gastrointestinal metastases (GIMs) are rare, and their prognosis is still poorly understood.

Objectives: To report clinical presentations, patient characteristics, therapeutic strategies, and prognosis of GIMs from RCC.

Methods: We retrospectively collected data from RCC patients presenting GIMs, in 10 French GETUG centers, between 2000 and 2021.

Results: We identified 74 patients with 87 GIMs, mostly gastric or duodenal. The median age at GIM diagnosis was 69 years and 76% of patients already had other metastases. GIMs occurred after a median duration of 5.4 years (IC95%=[4.2-7.1]) and 1.9 years (IC95%=[1.2-3.8]) from RCC diagnosis and first metastasis, respectively. GIMs were symptomatic in 52 patients (70%), with anemia in 41 patients (55%) and/or gastrointestinal bleeding in 31 patients (42%). Only 22 asymptomatic patients (30%) were fortuitously diagnosed. GIM management consisted of systemic treatment only in 29 GIMs (33%), local treatment only in 23 GIMs (26%), and both local and systemic treatment in 18 GIMs (21%). For 17 GIMs (20%), there was no therapeutic modification. After diagnosis of GIM, median overall survival was 19 months.

Conclusion: We report the largest retrospective cohort of GIMs in RCC patients. They should be suspected in case of anemia or gastrointestinal bleeding in any patient with a history of RCC. Their management varies widely depending on their location in the digestive tract and whether or not they are symptomatic.

Keywords: Gastrointestinal Hemorrhage; Gastrointestinal Tract; Metastasis; Renal Cell Carcinoma.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Anemia*
  • Carcinoma, Renal Cell* / drug therapy
  • Gastrointestinal Hemorrhage
  • Gastrointestinal Neoplasms*
  • Humans
  • Kidney Neoplasms* / drug therapy
  • Retrospective Studies